Skip to main content
OpenTrials
Completed

NCT Number: NCT05395013

Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)

The aim of the study is to evaluate the efficacy and safety of the various types of stents available for biliary drainage in patients with neoplastic stenosis of the common bile duct and to evaluate the adherence to the current guidelines available.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Biliary drainage before surgery or chemotherapy is a common practice in patients with neoplastic stenosis of the common bile duct, often required by the presence of clinical conditions such as the onset of cholangitis or severe jaundice.

The endoscopic approach has now been identified by the literature as the preferential drainage route, due to a lower incidence of adverse effects, liver or intraperitoneal metastases and lower costs associated with this technique compared to percutaneous drainage.

The latest guidelines from the European Society of Gastrointestinal Endoscopy recommend the placement of a 10 mm diameter self-expandable metal stent (SEMS) as the first choice for endoscopic drainage in patients with extra-hepatic biliary stenosis of neoplastic origin. Compared to plastic stents, SEMS placement is associated with a lower risk of developing stent dysfunction and/or cholangitis, lower risk of reintervention, and better patient survival.

However, among the various types of metal stents available, to date there is no agreement on which type is the most suitable, as data on efficacy and post-interventional morbidity and mortality of the fully or partially covered and uncovered metal stents are contradictory.

The aim of the study is to evaluate the efficacy and safety of the various types of stents available for biliary drainage in patients with neoplastic stenosis of the common bile duct and to evaluate the adherence to the current guidelines available.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Common bile duct stricture (i.e. jaundice and/or cholangitis) of malignant origin
  • Patients > 18 years old
  • Obtaining informed consent

Exclusion criteria

  • Lack of sufficient clinical and laboratory data to define clinical efficacy and/or follow-up available <1 month

Treatment and study plan

Primary outcomes

  1. Bilirubin decrease

    Time frame: From 2017 to 2021

    Rate of resolution of obstructive jaundice in short and long term (i.e. maintenance of patency and/or the need for reintervention) of the different types of biliary stent placed in patients with neoplastic stenosis of the common bile duct

Secondary outcomes

  1. Rate of adverse events

    Time frame: From 2017 to 2021

    Rate of periprocedural complications (i.e. bleeding, pancreatitis, cholecystitis) after biliary stent placement

  2. Rate of endoscopic reintervention

    Time frame: From 2017 to 2021

    Rate of stent disfunction requiring an additional endoscopic procedure

  3. Rate of biliary cannulation and successful stent placement

    Time frame: From 2017 to 2021

    Rate of biliary cannulation and successful stent placement

Sponsors and collaborators

Lead sponsor

Azienda Unità Sanitaria Locale della Romagna

Other

Registry information

Acronym: NEOSTENT

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
May 27, 2022
Registry last updated
Jun 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.